We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Review · November 18, 2020

Efficacy of Intravenous NEPA for the Prevention of CINV During Cisplatin- and Anthracycline Cyclophosphamide–Based Chemotherapy

Critical Reviews in Oncology / Hematology

 

Additional Info

Critical Reviews in Oncology / Hematology
Efficacy of Intravenous NEPA, a Fixed NK1/5-HT3 Receptor Antagonist Combination, for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) During Cisplatin- and Anthracycline Cyclophosphamide (AC)-Based Chemotherapy: A Review of Phase 3 Studies
Crit. Rev. Oncol. Hematol 2020 Nov 07;[EPub Ahead of Print], M Aapro, RM Navari, E Roeland, L Zhang, L Schwartzberg

Further Reading